Net Income

BioAdaptives completes its MyndSystem™ with a new nighttime nootropic, aiming to capture the overlooked market for overnight brain recovery.

Leveraging its Singapore gateway, Sabah is attracting billions in high-value, eco-friendly investments, aiming to become a leader in sustainable growth.

As global landmarks glow red for National Nurses Week, the celebration highlights a profession grappling with severe staffing shortages and systemic burnout.

With families facing months-long waits for care, Lyra Health is rolling out urgent and intensive virtual programs to treat severe youth mental health crises.

MarTech firm Banzai executes another reverse stock split to avoid delisting, but can strategic acquisitions outweigh its deep financial challenges?

AI fintech Corgi unleashes a record 28 actively managed thematic ETFs, offering hyper-niche strategies at a disruptive price point for investors.

Co-founded by Maria Shriver, MOSH raises $13M to scale its brain health nutrition brand, targeting a national grocery and Target rollout.

RVL Pharmaceuticals claims double-digit growth for its eye drop Upneeq, but as a private firm, its disruptive direct-to-consumer model operates outside public view.

The entertainment giant reported higher Q3 net income despite storms and weak consumer sentiment, leaning on AI-driven efficiencies and strategic acquisitions.

With a promising cancer pipeline, Crescent Biopharma heads to key May conferences to prove its strategy against fierce competition in the bispecific and ADC markets.

Twin Disc reverses a prior-year loss with a $3.3M profit, driven by a 19% sales jump and record backlog, signaling a strong strategic turnaround.

A new advisory firm, AssetBuilt, launches with 200+ years of expertise, targeting the complex and booming EV and battery manufacturing asset market.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

TIC Solutions reports a 108% revenue surge in Q1 after its NV5 acquisition, yet integration costs and debt deepen its net loss, setting a critical stage for its upcoming Investor Day.

Preclinical data for CITY-RBP4 shows promise in treating Stargardt disease, a leading cause of juvenile blindness with no approved therapies.

The Charleston firm's strategic hire of Cameron Dorsey signals a focused push to attract family office and private wealth for its East Coast expansion.

The maker of Hefty and Reynolds Wrap defies economic woes, reporting a 90% jump in net income and strong volume growth, fueled by strategic shifts.

Amble Health's new program offers 50% off weight loss drugs, but it requires patients to pay cash and potentially use non-FDA-approved medications.

Sinopec's new 'Fenghuo' AI agent isn't just a tool—it's a digital expert working alongside humans, signaling a major shift in industrial automation.

The mining giant launches cash tender offers and plans a new bond sale, a bold move to reduce debt and navigate the volatile commodities market.